SF3B1 and myelodysplastic syndrome: Additionally, a robust response was seen in patients with MDS with ≥15% ringed sideroblasts (MDS-RS; RBC-TI 42%, HI-E 69%) and MDS with an SF3B1 mutation (RBC-TI 44%, HI-E 77%).